Substance over
diversification at any cost.
You manage a family office with significant pharma/medtech/hospital assets. Generation transition is approaching. Diversification is the default recommendation, but substance concentration in pharma is often the rational choice when you understand the sector. We connect §34d/§34f compliance, healthcare sector depth, M&A for participation carve-outs and cross-generation structuring in a wealth mandate logic.
Diversification dogma vs. substance rationality
Standard family-office advisory recommends 60/40 diversification. For pharma families with 40-70% concentration this is often wrong, when sector understanding exists and operational knowhow creates value, concentration is rational. We make the substance-vs-diversification analysis with sector lens.
Generation transition without sector loss
Foundation models vs. holding models: both have pros/cons. Active pharma family with involved next gen: holding model. Passive family without operational next gen: foundation model. Inheritance tax optimization affects both differently.
§34d/§34f cross-border compliance
DACH + UK/CH pharma investments need different license frameworks. §34d in DE, FCA in UK, FINMA in CH. Cross-border structures must cover all three. Below 25% cap-table stake §34f may suffice - above 25% in family AG §34d is mandatory.
AME Pharma-Family Stair-Step
Wealth audit - pharma concentration analysis - §34d/§34f obligation - generation-transition setup
Family office setup, asset holding structures - foundation vs holding - cross-border setup
Quarterly reporting - co-invest structuring - hospital/MVZ stakes via AME Investment GmbH
How we work with pharma families
Wealth audit (3-5 weeks)
Cap-table mapping - pharma concentration analysis - §34d/§34f obligation check - generation mapping - cross-border status.
Strategy workshop (2-3 weeks)
Substance-vs-diversification frame - generation-transition wish - foundation vs holding preference - co-invest appetite - tax optimization.
Structuring §34d (6-10 weeks)
Family-office setup, asset-holding GmbH - cross-border vehicle (UK/CH) - foundation setup if chosen - earn-out structures for stakes.
Support (12-36 months)
Quarterly reporting - generation transition phase management - co-invest pipeline evaluation - AME Investment GmbH Q4 2026 connection.
Pharma-Family × other AME clusters
Pharma family-office mandates cross multiple sectors:
Healthcare family-office structuring - §34d for pharma holdings - generation transition
Family-holding carve-outs - earn-out structures - sell-side with §34d post-sale advisory
CSRD obligation for pharma holdings - ESG reporting setup - limited assurance
Pharma cold-chain energy - scope-3 reduction paths - site energy audit
Tools for pharma families
Related profiles
If you have a different role:
Common questions from pharma families
Why AME STRATICON for pharma families?
§34d/§34f dual license
Marlies Machens (management) as licensed insurance + financial investment broker - mandatory license for family-office mandates
Bertram + Marlies tandem
Bertram Engelhardt 20+ years pharma/healthcare M&A - Marlies §34d wealth + healthcare strategy - dual lead
AME Investment GmbH Q4 2026
Own investment vehicle for co-invest with family offices - healthcare pipeline from AME M&A mandates - BaFin notification ongoing
§34d Structuring Call with AME
30 min with Marlies Machens (§34d lead) or Bertram Engelhardt (pharma M&A). Free pre-briefing on wealth volume + generation setup.
§34d Structuring Call with AME